AstraZeneca Baxdrostat Secures FDA Approval for Hypertension FDA approved baxdrostat for hypertension. AstraZeneca's drug is first-in-class. Phase 3 data supported the approval. This marks a new treatment paradigm. AstraZeneca's baxdrostat, an aldosterone synthase inhibitor (ASI), received FDA approval for treating hypertension. This significant milestone follows robust Phase 3 trial results. The trials demonstrated superior blood pressure reduction compared to placebo, meeting its primary endpoint. Baxdrostat offers a novel mechanism of action, targeting aldosterone production directly. The FDA's decision underscores the agency's recognition of unmet needs in hypertension management. This approval allows AstraZeneca to market baxdrostat immediately in the US. The regulatory pathway involved standard New Drug Application (NDA) procedures, adhering to 21 CFR Part 314. EMA review for baxdrostat is currently ongoing, with a decision anticipated by Q4 2026. This approval impacts the competitive landscape, challenging existing therapies like diuretics and ACE inhibitors. Competitors such as Novartis (Entresto) and Bayer (Kerendia) may face increased pressure. Baxdrostat's launch strengthens AstraZeneca's cardiovascular portfolio, contributing to its projected revenue growth. The drug is expected to be available to patients by Q3 2026.